Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 21, 2022, serves as a transaction notification for the month of December 2022. The document discloses share purchases made by Persons Discharging Managerial Responsibilities (PDMRs) and does not contain financial performance results for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of insider trading activity.
Material Changes and Transactions
The filing details three specific share purchase transactions executed on December 20, 2022, by company directors:
- Sir Jonathan Symonds (Non-Executive Chair): Purchased 2,100 Ordinary Shares at £14.1720 per share on the London Stock Exchange (XLON).
- Dr. Hal Barron (Non-Executive Director): Purchased 458 American Depositary Shares (ADSs) at $34.8600 per share on the New York Stock Exchange (XNYS).
- Dr. Vishal Sikka (Independent Non-Executive Director): Purchased 1,147 American Depositary Shares (ADSs) at $34.8600 per share on the New York Stock Exchange (XNYS).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned transactions.
Investor Verification Checklist
- Verify the total number of shares purchased by each director against their total holdings to assess ownership concentration.
- Confirm the transaction prices (£14.1720 and $34.8600) against the closing market prices for GSK on December 20, 2022.
- Review the company's most recent Form 20-F or earnings release for actual financial performance metrics, as they are absent from this filing.